Symvess

1 INDICATIONS AND USAGE SYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. SYMVESS™ is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. ( 1 )

2 DOSAGE AND ADMINISTRATION For surgical vascular implantation only. SYMVESS is administered by surgical implantation to replace the injured extremity artery. The anatomical location and length are decided upon at the discretion of the implanting surgeon and based on the appropriate preoperative clinical evaluation, vessel mapping and/or imaging. ( 2.1 ) SYMVESS may be trimmed to provide the length required for each vascular repair. Additionally, a single SYMVESS can be cut into different lengths and used to repair more than one injured extremity artery in the same patient. Each SYMVESS unit is for administration to a single patient only. ( 2.1 ) 2.1 Dosage SYMVESS is administered by surgical implantation to replace the injured extremity artery. The anatomical location in the extremity and length required should be determined by the surgeon implanting the graft based on the appropriate pre-operative clinical evaluation, vessel mapping and/or imaging, and intra-operative considerations. SYMVESS is provided as follows: 6 mm in internal diameter and 42 cm in length. Once removed from packaging, its usable length is approximately 40 cm. Each package (i.e., box containing Tyvek ® -sealed tray) contains one SYMVESS unit for administration to a single patient only. SYMVESS may be trimmed to provide the length required for the artery replacement. SYMVESS can be trimmed to replace more than one injured extremity artery in the same patient. 2.2 Handling of SYMVESS Supplies: The following supplies are not included in the carton, but may be needed for the handling of SYMVESS: 1) Sterile basin (as needed) – see Step 8 for details 2) Sheath tunneler (as needed) – see Section 2.3 and Step 3 for details SYMVESS is to be handled in an appropriate surgical environment as follows: Step 1: SYMVESS box contains a plastic thermoformed tray with a Tyvek ® lid. Open the box and remove the plastic tray ( Figure 1 ). Figure 1: SYMVESS box and plastic tray Step 2: After removing the tray from the box, check the FreezeAlert temperature indicator ( Figure 2 ) attached to the side of the tray. If a check mark is displayed, SYMVESS has not been exposed to freezing temperatures and can be used. If an “X” is displayed, SYMVESS has been exposed to freezing temperatures and should NOT be used. Figure 2: FreezeAlert Temperature indicator Step 3: Two operators (one sterile operator and one non-sterile operator) are required to remove the sterile packaging bag containing SYMVESS from the plastic tray. Inspect the plastic tray to check for damage which can lead to loss in sterility of the SYMVESS. Do not open the tray for further use if the product is expired or has visible damage. If packaging is intact and within date of acceptable use, the non-sterile operator pulls back the Tyvek ® lid by the corner tab to open the plastic tray containing the sterile packaging bag ( Figure 3a and 3b ). Take careful steps to avoid touching the sterile contents inside the tray ( Figure 3c ). Figure 3a: Non-sterile operator pulls back the Tyvek ® lid by the corner tab Figure 3b: Non-sterile operator opens the plastic tray containing the sterile packaging bag Figure 3c displays the components of SYMVESS within the plastic tray. Figure 3c: SYMVESS with each component Step 4: The non-sterile operator holds the bottom of the plastic tray with one hand and opens the Tyvek ® lid with the other. The sterile operator removes the sterile packaging bag from the tray by grasping the ports (i.e., tubing) at the ends of the sterile packaging bag to remove the sterile packaging bag from the tray ( Figure 4 ). Place the sterile packaging bag on a sterile surface. Figure 4: Sterile operator (grey gown and gloves; left) removes the packaging bag from plastic tray by grasping the ports (tubing) while non-sterile operator (white gloves; right) holds the plastic tray and opens the Tyvek ® lid Step 5 : SYMVESS is suspended in sterile saline inside the packaging. The sterile operator cuts one or both o…

5 WARNINGS AND PRECAUTIONS Graft Rupture. ( 5.1 ) Anastomotic Failure. ( 5.2 ) Thrombosis. ( 5.3 ) Transmission of Infectious Diseases ( 5.4 ) 5.1 Graft Rupture Vascular graft rupture has occurred in patients treated with SYMVESS [see Clinical Trials Experience (6.1) ] . Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia. Follow appropriate procedures for handling and administering SYMVESS [see Dosage and Administration (2) ] . 5.2 Anastomotic Failure Anastomotic failure has occurred in patients treated with SYMVESS [see Clinical Trials Experience (6.1) ] . In clinical studies of SYMVESS, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding, swelling or worsening pain at the surgical site or changes in color of overlying skin. Follow appropriate procedures for handling and administering SYMVESS [see Dosage and Administration (2) ] . 5.3 Thrombosis Thrombosis has occurred in patients treated with SYMVESS [see Clinical Trials Experience (6.1) ] . In clinical trials of SYMVESS, patients received antiplatelet therapy following implantation of SYMVESS to reduce the risk of thrombosis. The risk of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment with SYMVESS. 5.4 Transmission of Infectious Diseases SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or infectious agents. The cells used in the manufacture of SYMVESS are derived from a donor who met the donor eligibility requirements for transmissible infectious diseases which includes screening and testing of risks associated with human immunodeficiency virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis ( Treponema pallidum) . The cell banks are tested negative for human and animal viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma. While all animal-derived reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, these measures do not eliminate the risk of transmitting these or other transmissible infectious diseases and disease agents. Fetal bovine serum is sourced to minimize the risk of transmitting a prion protein that causes bovine spongiform encephalopathy and the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob disease. No transmissible agent infections have been reported during clinical testing.

4 CONTRAINDICATIONS DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries.

8.1 Pregnancy Risk Summary The limited clinical data that are available with SYMVESS use in pregnant women are insufficient to inform a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with SYMVESS to assess whether it can cause harm to the mother or fetus when administered to a pregnant woman. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

6 ADVERSE REACTIONS The most common adverse reactions (incidence ≥3%) were thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Humacyte Global, Inc. at 1-833-591-0081 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a product cannot be directly compared to adverse reaction rates in clinical trials of other products, and they may not reflect the rates observed in real-world clinical practice. The safety data described in this section reflect exposure to SYMVESS in one single arm, open-label study in patients requiring vascular replacement or reconstruction for life or limb threatening vascular trauma, Study 1 (CLN-PRO-V005; NCT03005418). A total of 54 adults received extremity implantation of SYMVESS as a vascular conduit. The patient population ranged in age from 18 to 72 years (mean age 33 years). Each patient received a SYMVESS implant ranging in length from 1 to 35 cm (mean length 10.1 cm). The most frequently occurring adverse reactions are shown in Table 1 . Table 1 Adverse Reactions Occurring with a Frequency of ≥3% in Study 1 Adverse Reaction Adverse Reaction Frequency based on up to 3 years follow-up data [median 191 days (range 1-1134 days)] Extremity Patients (%) Extremity patients are with arterial repair in upper or lower limbs (n=54) Vascular graft thrombosis 15 (28%) Pyrexia (fever) 9 (17%) Pain 8 (15%) Anastomotic stenosis 5 (9%) Vascular graft rupture or anastomotic failure 4 (7%) Vascular graft infection 3 (6%) Long term follow-up of up to 36 months in Study 1 is ongoing. At the data cut-off date, 7 out of 54 patients in the extremity group have completed the study (i.e., completed 36 months of follow-up). The safety of SYMVESS beyond 36 months was not evaluated in the clinical studies for this indication.